DBR Canada Inc.
DBR Canada Inc. (DBR) is a privately owned, federally incorporated Canadian company, established in 2001. DBR provides Canadian-focused market access related services specializing in reimbursement projects involving oncology and non-oncology prescription drugs (oral, injectable), including mono and combination therapies, immunotherapies, antineoplastic agents, radiopharmaceuticals, gene editing technologies, biosimilars, as well as work supporting the reimbursement of medical devices, and nutritional products.
Key Capabilities and Experience
DBR’s key capabilities and experience involve supporting all aspects of the preparation, management, and delivery of complete pre-NOC and post-NOC reimbursement submissions to:
- Canada’s Drug Agency (CDA-AMC, formerly CADTH)
- Institut national d'excellence en santé et en services sociaux (INESSS)
- Federal-Territorial-Provincial (F/T/P) Ministries of Health
- Provincial Cancer Agencies
- Canadian Private Insurers and Claims Adjudicators
- Hospital Pharmacy & Therapeutics (P&T) Committees
To date DBR has successfully supported clients with the management, preparation, and delivery of:
- 75 CDA-AMC Submissions
- 34 Direct to Federal-Provincial-Territorial (F/P/T) Submissions
- 106 INESSS Submissions
- 111 Private Payer Submissions
- 35 Private Payer Reimbursement Status Reports
- 27 Hospital P&T Submission Kits
Our Team and Expertise
The strength and quality of our services is based on our ability to assemble senior-level project teams where each team member typically has 20 years or more experience within their respective discipline. Key areas of expertise amongst team members range from overall submission preparation, management, and delivery to the ability to perform systematic literature reviews, clinical evidence summarization, indirect treatment comparisons, pharmacoeconomics, and budget impact analysis.
The power of this dynamic cross-functional group is what facilitates DBR’s “small but mighty” ability to help support every aspect of a client’s needs when it comes to meeting the submissions requirements of the various public and private payers across a wide range of submission types — from new drug, new medical device, or new nutritional product submissions, to new indications, formulations, strengths, or formats of Health Canada-approved products.
Contact Us
For more information about our services and how we can support your reimbursement needs in Canada please contact:
|
